ClinicalTrials.gg

Program

Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb

A development code. Also written as “Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI”, “Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII” and “Pneumococcal Conjugate Vaccine formulation 1”.

In Sanofi’s pipeline, 21-valent conjugate vaccine. Its studies are mostly in Chickenpox, led by Sanofi.

Furthest: phase 2, since May 18, 20202 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi20 open or runningphase 2since May 18, 2020May 18, 2020none ahead
  • Named in Sanofi’s own pipeline as SP0202, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2020First study: phase 2 study in Pneumococcal ImmunisationFirst studyNCT04398706 · 852 enrolled · United States, Canada, Honduras and more
  2. Oct 5, 2020Phase 2 study in Pneumococcal ImmunizationNCT04583618 · 750 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“21-valent conjugate vaccine”the company's pipeline, read by Claude · source
“Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb”name, read by Claude

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04583618Pneumococcal Immunization · United States2CompletedAug 9, 2021750
NCT04398706Pneumococcal Immunisation · United States, Canada, Honduras and more2CompletedAug 10, 2023852

How it is read

Names in the registry

  • “Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb”, 1 entry
  • “Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI”, 1 entry
  • “Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII”, 1 entry
  • “Pneumococcal Conjugate Vaccine formulation 1”, 1 entry
  • “Pneumococcal Conjugate Vaccine formulation 2”, 1 entry

Codes read as this program: SP0202.

Conditions, from the studies’ own filings

First seen by our ledger Nov 14, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.